ASCP and Pfizer Unveil Innovative Funding Initiative
The American Society for Clinical Pathology (ASCP), in partnership with Pfizer and supported by the American Society of Clinical Oncology (ASCO), has launched an exciting new opportunity to advance the field of biomarker testing in metastatic colorectal cancer (mCRC). This initiative is focused on supporting multiple Quality Improvement (QI) grant projects, each funded up to $250,000, designed to transform treatment selection processes for mCRC patients. The program is set to officially commence in the near future, with ASCP overseeing its management.
Objectives of the Quality Improvement Initiative
This ambitious multi-year initiative seeks to tackle ongoing challenges within the realm of molecular testing, communication, and coordination of care in mCRC treatment. The primary goal is to improve the quality of biomarker testing, which plays a critical role in determining the appropriate frontline therapies for patients. Studies funded through these grants will focus on optimizing testing practices for significant biomarkers such as RAS (KRAS/NRAS) mutations, BRAF mutations, HER2 amplification, and microsatellite instability (MSI) / mismatch repair (MMR) status, fully aligning with National Comprehensive Cancer Network (NCCN) guidelines.
Enhancing Collaboration Among Healthcare Professionals
The QI grant projects will be designed as multidisciplinary health system implementations centered around pathology. Their focus will be on community-based healthcare institutions as the primary beneficiaries. Collaborative efforts will unite pathologists, laboratory professionals, oncologists, and various members of the cancer care team, fostering improved coordination across these disciplines to enhance evidence-based care delivery.
Ali Brown, the Interim CEO of ASCP, expressed the underlying philosophy of this effort by stating, "By investing in pathology-led quality improvement, we are strengthening the entire cancer care team. This RFP supports healthcare institutions in building the skills, workflows, and partnerships needed to deliver high-quality biomarker testing, enabling oncologists to make informed treatment decisions and improving care for patients with metastatic colorectal cancer."
Utilizing Cutting-Edge Technology for Improvement
Projects that receive funding through this initiative will utilize ASCP's Performance and Diagnostic Insights (PDI) platform, which facilitates real-time data aggregation and analytics. This technology will empower institutions to assess existing practices critically, pinpoint variations in biomarker testing workflows, and initiate targeted improvements that enhance both efficiency and timely results.
Key Program Goals
The program aims to achieve several crucial objectives, including:
- Assessing current biomarker testing protocols and identifying variations in test ordering practices.
- Evaluating turnaround times and optimizing reporting workflows for greater operational efficiency.
- Fostering recommendations that address communication gaps, thereby ensuring timely sharing of biomarker test results with the healthcare team.
- Creating pathways for accelerated molecular diagnostics to support ideal frontline treatment decisions.
- Enhancing patient safety through accordance with established guidelines for testing and therapy selection.
- Boosting the capabilities of healthcare teams by providing pathology and laboratory professionals with essential tools and skills for better communication and coordination of care.
Wider Impact on Metastatic Colorectal Cancer Care
Moreover, the insights and best practices derived from the funded QI projects will be widely disseminated to promote scalable advancements across the board for mCRC care. This initiative exemplifies a commitment to continuous improvement in healthcare practices, ultimately benefiting the wider community and ensuring that more patients receive the highest quality of care.
How to Participate in the Grant Proposal Process
Organizations interested in partaking in this opportunity are encouraged to thoroughly review the complete RFP for eligibility criteria, application requirements, and important timelines. This is an excellent chance for institutions to contribute to transformative changes in cancer care.
About the Partners
The ASCP, recognized as the largest professional membership organization for pathologists and laboratory professionals globally, is dedicated to advancing excellence in pathology and laboratory medicine through education, advocacy, certification, and innovation.
On the other hand, Pfizer Oncology is at the forefront of developing innovative cancer care solutions. Their robust portfolio consists of cutting-edge therapies addressing various cancer types, including breast and lung cancers. Driven by a deep commitment to scientific advancement, Pfizer aims to improve patient outcomes and enhance the quality of life for those battling cancer.
Frequently Asked Questions
What is the purpose of the ASCP and Pfizer funding initiative?
The initiative aims to support projects that enhance biomarker testing for metastatic colorectal cancer, ensuring informed treatment decisions and improving patient care.
How much funding is available for each project?
Each project can receive funding of up to $250,000.
Who can apply for the grants?
Organizations involved in healthcare and associated institutions focusing on cancer care can submit proposals.
When will the funding opportunity open?
The RFP will open soon, providing details about application procedures and eligibility.
What technologies will be used in the funded projects?
Projects will utilize ASCP's Performance and Diagnostic Insights (PDI) platform for real-time data analytics to support continuous improvement in biomarker testing.
